Company intelligence / Profile preview

CimCure

Amsterdam, North Holland, Netherlandscimcure.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CimCure is developing vaccine-based cancer immunotherapies targeting tumor vasculature using its proprietary iBoost conjugate vaccine platform. The approach aims to inhibit tumor growth by eradicating blood vessels feeding the tumor, potentially overcoming resistance seen with other angiostatic therapies. Early proof-of-concept has been demonstrated, and the company is advancing towards clinical development, including a consortium project for glioblastoma combining vaccines and CAR T cells

Therapeutic areas: Oncology
Modalities: Conjugate vaccines (proprietary iBoost technology)CAR T cell therapy (in combination with vaccines)
Industry: Biotech

Drug pipeline

2 assets

vimentin vaccine

Preclinical

1 more asset in the full pipeline.

Partnerships

Eurostars consortium partners in Switzerland and France for glioblastoma project

Beyond the preview

Go deeper on CimCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CimCure.